These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 15017380

  • 1. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
    Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.
    Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
    [Abstract] [Full Text] [Related]

  • 2. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [Abstract] [Full Text] [Related]

  • 3. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 4. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.
    Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Yamamoto M, Alvarez RD, Curiel DT.
    Gene Ther; 2004 Apr; 11(7):645-8. PubMed ID: 15029227
    [Abstract] [Full Text] [Related]

  • 5. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T, Hamada K, Zhang Z, Okada H, Tagawa M, Kamidono S, Kawabata M, Gotoh A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4342-8. PubMed ID: 15240520
    [Abstract] [Full Text] [Related]

  • 6. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
    Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker SD, Wang MH, Mahasreshti PJ, Hemminki A, Gonzalez-Baron M, Barnes MN, Pustilnik TB, Siegal GP, Alvarez RD, Curiel DT.
    Clin Cancer Res; 2001 Aug 01; 7(8):2496-504. PubMed ID: 11489832
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of tumor-specific promoter activities in melanoma.
    Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, Curiel DT, Zhu ZB.
    Gene Ther; 2005 Feb 01; 12(4):330-8. PubMed ID: 15696177
    [Abstract] [Full Text] [Related]

  • 8. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
    Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A.
    J Gene Med; 2003 Apr 01; 5(4):300-10. PubMed ID: 12692864
    [Abstract] [Full Text] [Related]

  • 9. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells.
    Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M.
    Surgery; 2005 Aug 01; 138(2):299-305. PubMed ID: 16153440
    [Abstract] [Full Text] [Related]

  • 10. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors.
    Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT.
    Cancer Res; 2000 Aug 15; 60(16):4305-10. PubMed ID: 10969765
    [Abstract] [Full Text] [Related]

  • 11. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
    Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM.
    Mol Ther; 2004 Oct 15; 10(4):758-67. PubMed ID: 15451460
    [Abstract] [Full Text] [Related]

  • 12. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
    Määttä AM, Korja S, Venhoranta H, Hakkarainen T, Pirinen E, Heikkinen S, Pellinen R, Mäkinen K, Wahlfors J.
    Int J Mol Med; 2006 Nov 15; 18(5):901-8. PubMed ID: 17016620
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA, Kao C.
    J Gene Med; 2006 Jun 15; 8(6):679-89. PubMed ID: 16570242
    [Abstract] [Full Text] [Related]

  • 14. Transcriptional regulatory regions of the survivin gene activate an exogenous suicide gene in human tumors and enhance the sensitivity to a prodrug.
    Kawamura K, Yu L, Tomizawa M, Shimozato O, Ma G, Li Q, Sato A, Yang Y, Suzuki T, Abdel-Aziz NM, Tagawa M.
    Anticancer Res; 2007 Jun 15; 27(1A):89-93. PubMed ID: 17352220
    [Abstract] [Full Text] [Related]

  • 15. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
    Zhu HJ, Zhang ZQ, Zeng XF, Wei SS, Zhang ZW, Guo YL.
    Cancer Gene Ther; 2004 Apr 15; 11(4):263-72. PubMed ID: 14963492
    [Abstract] [Full Text] [Related]

  • 16. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
    Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N.
    Oncogene; 2004 Jan 15; 23(2):386-94. PubMed ID: 14724567
    [Abstract] [Full Text] [Related]

  • 17. Regulatory regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells.
    Tomizawa M, Saisho H, Tagawa M.
    Anticancer Res; 2003 Jan 15; 23(4):3273-7. PubMed ID: 12926063
    [Abstract] [Full Text] [Related]

  • 18. Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer.
    Oshikiri T, Miyamoto M, Hiraoka K, Shichinohe T, Kawarada Y, Kato K, Suzuoki M, Nakakubo Y, Kondo S, Dosaka-Akita H, Kasahara N, Katoh H.
    Cancer Gene Ther; 2006 Sep 15; 13(9):856-63. PubMed ID: 16710347
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter.
    Berry NB, Cho YM, Harrington MA, Williams SD, Foley J, Nephew KP.
    Gynecol Oncol; 2004 Mar 15; 92(3):896-904. PubMed ID: 14984958
    [Abstract] [Full Text] [Related]

  • 20. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
    Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, Li H, Reynolds PN, Dmitriev I, Vickers SM, Huibregtse K, Curiel DT.
    Cancer Gene Ther; 2001 Dec 15; 8(12):990-6. PubMed ID: 11781662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.